161 related articles for article (PubMed ID: 24376158)
21. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma.
Giakoustidis AE; Giakoustidis DE
Immunotherapy; 2017 Jan; 9(2):197-206. PubMed ID: 28128716
[TBL] [Abstract][Full Text] [Related]
22. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Gish RG; Finn RS; Marrero JA
Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427
[TBL] [Abstract][Full Text] [Related]
23. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
Duvoux C; Toso C
Transplant Rev (Orlando); 2015 Jul; 29(3):168-74. PubMed ID: 26071984
[TBL] [Abstract][Full Text] [Related]
24. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.
Ferreiro AO; Vazquez-Millán MA; López FS; Gutiérrez MG; Diaz SP; Patiño MJ
Transplant Proc; 2014 Dec; 46(10):3496-501. PubMed ID: 25498079
[TBL] [Abstract][Full Text] [Related]
25. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.
Toso C; Merani S; Bigam DL; Shapiro AM; Kneteman NM
Hepatology; 2010 Apr; 51(4):1237-43. PubMed ID: 20187107
[TBL] [Abstract][Full Text] [Related]
26. [Liver transplantation: personalized immunosuppression in patients with hepatitis C virus infection and hepatocellular carcinoma].
Rubín A; Berenguer M
Gastroenterol Hepatol; 2013 Jan; 36(1):48-57. PubMed ID: 22578313
[TBL] [Abstract][Full Text] [Related]
27. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed?
Castroagudín JF; Molina-Pérez E; Ferreiro-Iglesias R; Abdulkader I; Otero-Antón E; Tomé S; Varo-Pérez E
Transplant Proc; 2012; 44(6):1565-7. PubMed ID: 22841215
[TBL] [Abstract][Full Text] [Related]
28. [Liver transplantation for hepatocellular carcinoma and potential application of PSI].
Decaens T; Duvoux C
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S257-62. PubMed ID: 20004332
[TBL] [Abstract][Full Text] [Related]
29. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Grigg SE; Sarri GL; Gow PJ; Yeomans ND
Aliment Pharmacol Ther; 2019 May; 49(10):1260-1273. PubMed ID: 30989721
[TBL] [Abstract][Full Text] [Related]
30. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
[TBL] [Abstract][Full Text] [Related]
31. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.
Vivarelli M; Cucchetti A; Piscaglia F; La Barba G; Bolondi L; Cavallari A; Pinna AD
Liver Transpl; 2005 May; 11(5):497-503. PubMed ID: 15838913
[TBL] [Abstract][Full Text] [Related]
32. Surgical Resection for Lymph Node Metastasis After Liver Transplantation for Hepatocellular Carcinoma.
Ikegami T; Yoshizumi T; Kawasaki J; Nagatsu A; Uchiyama H; Harada N; Harimoto N; Itoh S; Motomura T; Soejima Y; Maehara Y
Anticancer Res; 2017 Feb; 37(2):891-895. PubMed ID: 28179348
[TBL] [Abstract][Full Text] [Related]
33. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
Barbier L; Fuks D; Pessaux P; Muscari F; Le Treut YP; Faivre S; Belghiti J
Ann Surg Oncol; 2013 Oct; 20(11):3603-9. PubMed ID: 23715965
[TBL] [Abstract][Full Text] [Related]
34. The evolving landscape of therapeutic drug development for hepatocellular carcinoma.
Chong DQ; Tan IB; Choo SP; Toh HC
Contemp Clin Trials; 2013 Nov; 36(2):605-15. PubMed ID: 23591326
[TBL] [Abstract][Full Text] [Related]
35. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
Kneteman NM; Oberholzer J; Al Saghier M; Meeberg GA; Blitz M; Ma MM; Wong WW; Gutfreund K; Mason AL; Jewell LD; Shapiro AM; Bain VG; Bigam DL
Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305
[TBL] [Abstract][Full Text] [Related]
36. Treatment of early hepatocellular carcinoma: How to predict and prevent recurrence.
Andreana L; Burroughs AK
Dig Liver Dis; 2010 Jul; 42 Suppl 3():S249-57. PubMed ID: 20547311
[TBL] [Abstract][Full Text] [Related]
37. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Vivarelli M; Dazzi A; Zanello M; Cucchetti A; Cescon M; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Transplantation; 2010 Jan; 89(2):227-31. PubMed ID: 20098287
[TBL] [Abstract][Full Text] [Related]
38. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
[TBL] [Abstract][Full Text] [Related]
39. [Review and prospect of clinical study on liver transplantation of hepatocellular carcinoma].
Huang XW; Zhou J
Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):81-83. PubMed ID: 29804370
[TBL] [Abstract][Full Text] [Related]
40. Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence.
Vivarelli M; Risaliti A
World J Gastroenterol; 2011 Nov; 17(43):4741-6. PubMed ID: 22147974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
